Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation - Trial NCT06280768
Access comprehensive clinical trial information for NCT06280768 through Pure Global AI's free database. This Phase 1 trial is sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd and is currently Not yet recruiting. The study focuses on Atrial Fibrillation. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing Suncadia Pharmaceuticals Co., Ltd
Timeline & Enrollment
Phase 1
Mar 01, 2024
Dec 31, 2024
Primary Outcome
Incidence and severity of adverse events (including bleeding events)
Summary
This study is an open-label Phase Ib clinical study with the primary objective of evaluating
 the safety and tolerability of multiple subcutaneous injections of SHR-2004 injection in
 patients with atrial fibrillation, and the secondary objective is to evaluate its
 pharmacokinetic (PK), pharmacodynamic (PD) and immunogenicity characteristics.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06280768
Non-Device Trial